

RESEARCH

Open Access

TNFRSF11B computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients

Ju X Huang^{1†}, L Wang^{1*†}, Ming H Jiang^{2†}

Abstract

Background: *TNFRSF11B* computational development network construction and analysis of frontal cortex of HIV encephalitis (HIVE) is very useful to identify novel markers and potential targets for prognosis and therapy.

Methods: By integration of gene regulatory network infer (GRNInfer) and the database for annotation, visualization and integrated discovery (DAVID) we identified and constructed significant molecule *TNFRSF11B* development network from 12 frontal cortex of HIVE-control patients and 16 HIVE in the same GEO Dataset GDS1726.

Results: Our result verified *TNFRSF11B* developmental process only in the downstream of frontal cortex of HIVE-control patients (*BST2*, *DGKG*, *GAS1*, *PDCD4*, *TGFBR3*, *VEZF1* inhibition), whereas in the upstream of frontal cortex of HIVE (*DGKG*, *PDCD4* activation) and downstream (*CFDP1*, *DGKG*, *GAS1*, *PAX6* activation; *BST2*, *PDCD4*, *TGFBR3*, *VEZF1* inhibition). Importantly, we datamined that *TNFRSF11B* development cluster of HIVE is involved in T-cell mediated immunity, cell projection organization and cell motion (only in HIVE terms) without apoptosis, plasma membrane and kinase activity (only in HIVE-control patients terms), the condition is vital to inflammation, brain morphology and cognition impairment of HIVE. Our result demonstrated that common terms in both HIVE-control patients and HIVE include developmental process, signal transduction, negative regulation of cell proliferation, RNA-binding, zinc-finger, cell development, positive regulation of biological process and cell differentiation.

Conclusions: We deduced the stronger *TNFRSF11B* development network in HIVE consistent with our number computation. It would be necessary of the stronger *TNFRSF11B* development function to inflammation, brain morphology and cognition of HIVE.

Background

The neurodegenerative process in HIV encephalitis (HIVE) is associated with cognitive impairment with extensive damage to the dendritic and synaptic structure. Several mechanisms might be involved in including release of neurotoxins, oxidative stress and decreased activity of neurotrophic factors [1]. The effect of HIV on brain has been studied by several researchers. Such as, decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without

cocaine abuse; Magnetic resonance imaging and spectroscopy of the brain in HIV disease; Analysis of the effects of injecting drug use and HIV-1 infection on 18F-FDG PET brain development [2-4]. *TNFRSF11B* computational development network construction and analysis of the frontal cortex of HIV encephalitis (HIVE) is very useful to identify novel markers and potential targets for prognosis and therapy.

TNFRSF11B is one out of 50 genes identified as high expression in frontal cortex of HIV encephalitis (HIVE) vs HIVE-control patients. *TNFRSF11B* has been proved to be concerned with molecular function of receptor, and biological process of developmental processes, skeletal development and mesoderm development (DAVID

* Correspondence: wanglin98@tsinghua.org.cn

† Contributed equally

¹Biomedical Center, School of Electronics Engineering, Beijing University of Posts and Telecommunications, Beijing, 100876, China

Full list of author information is available at the end of the article

database). *TNFRSF11B*'s relational study also can be seen in these papers [5-10]. However, the molecular mechanism concerning *TNFRSF11B* development construction in HIVE has little been addressed.

In this paper, by integration of gene regulatory network infer (GRNInfer) and the database for annotation, visualization and integrated discovery (DAVID) we identified and constructed significant molecule *TNFRSF11B* development network from 12 frontal cortex of HIVE-control patients and 16 HIVE in the same GEO Dataset GDS1726. Our result verified *TNFRSF11B* developmental process only in the downstream of frontal cortex of HIVE-control patients (*BST2*, *DGKG*, *GAS1*, *PDCD4*, *TGFBR3*, *VEZFI* inhibition), whereas in the upstream of frontal cortex of HIVE (*DGKG*, *PDCD4* activation) and downstream (*CFDP1*, *DGKG*, *GAS1*, *PAX6* activation; *BST2*, *PDCD4*, *TGFBR3*, *VEZFI* inhibition). Importantly, we datamined that *TNFRSF11B* development cluster of HIVE is involved in T-cell mediated immunity, cell projection organization and cell motion (only in HIVE terms) without apoptosis, plasma membrane and kinase activity (only in HIVE-control patients terms), the condition is vital to inflammation, brain morphology and cognition impairment of HIVE. Our result demonstrated that common terms in both HIVE-control patients and HIVE include developmental process, signal transduction, negative regulation of cell proliferation, RNA-binding, zinc-finger, cell development, positive regulation of biological process and cell differentiation, therefore we deduced the stronger *TNFRSF11B* development network in HIVE consistent with our number computation. It would be necessary of the stronger *TNFRSF11B* development function to inflammation, brain morphology and cognition of HIVE. *TNFRSF11B* development interaction module construction in HIVE can be a new route for studying the pathogenesis of HIVE. Our construction of *TNFRSF11B* development network may be useful to identify novel markers and potential targets for prognosis and therapy of HIVE.

Methods

Microarray Data

We used microarrays containing 12558 genes from 12 frontal cortex of HIVE-control patients and 16 HIVE in the same GEO Dataset GDS1726 [1]. HIVE-control patients mean normal adjacent frontal cortex tissues of HIV encephalitis (HIVE) and no extensive damage to the dendritic and synaptic structure.

Gene Selection Algorithms

50 molecular markers of the frontal cortex of HIVE were identified using significant analysis of microarrays (SAM). SAM is a statistical technique for finding significant genes in a set of microarray experiments. The

input to SAM is gene expression measurements from a set of microarray experiments, as well as a response variable from each experiment. The response variable may be a grouping like untreated, treated, and so on. SAM computes a statistic d_i for each gene i , measuring the strength of the relationship between gene expression and the response variable. It uses repeated permutations of the data to determine if the expression of any genes is significantly related to the response. The cutoff for significance is determined by a tuning parameter δ , chosen by the user based on the false positive rate. We normalized data by \log_2 , and selected two class unpaired and minimum fold change = 1.52. Here we chose the 50 top-fold significant (high expression genes of HIVE compared with HIVE-control patients) genes under the false-discovery rate and q-value as 9.12%. The q-value (invented by John Storey [11]) for each gene is the lowest false discovery rate at which that gene is called significant. It is like the well-known p-value, but adapted to multiple-testing situations.

Network Establishment of Candidate Genes

The entire network was constructed using GRNInfer [12] and GVEdit tools. GRNInfer is a novel mathematic method called GNR (Gene Network Reconstruction tool) based on linear programming and a decomposition procedure for inferring gene networks. The method theoretically ensures the derivation of the most consistent network structure with respect to all of the datasets, thereby not only significantly alleviating the problem of data scarcity but also remarkably improving the reconstruction reliability. The following Equation (1) represents all of the possible networks for the same dataset.

$$J = (X' - A)U\Lambda^{-1}V^T + YV^T = \hat{J} + YV^T \quad (1)$$

We established network based on the 50 top-fold distinguished genes and selected parameters as λ 0.0 because we used one dataset, threshold 0.000001. λ is a positive parameter, which balances the matching and sparsity terms in the objective function. Using different thresholds, we can predict various networks with different edge density.

Functional Annotation Clustering

The DAVID Gene Functional Clustering Tool provides typical batch annotation and gene-GO term enrichment analysis for highly throughput genes by classifying them into gene groups based on their annotation term co-occurrence [13,14]. The grouping algorithm is based on the hypothesis that similar annotations should have similar gene members. The functional annotation clustering integrates the same techniques of Kappa statistics to measure the degree of the common genes between

two annotations, and fuzzy heuristic clustering to classify the groups of similar annotations according to kappa values.

Results

Identification of HIVE Molecular Markers

TNFRSF11B is one out of 50 genes identified as high expression in frontal cortex of HIV encephalitis (HIVE) vs HIVE-control patients. We normalized data by log₂, and selected two class unpaired and minimum fold change = 1.52. Here we chose the 50 top-fold significant (high expression genes of HIVE compared with HIVE-control patients) genes under the false-discovery rate and q-value as 9.12%. We identified potential HIVE molecular markers and chose the 50 top-fold significant positive genes from 12558 genes from 12 frontal cortex of HIVE-control patients and 16 HIVE in the same GEO Dataset GDS1726 including tumor necrosis factor receptor superfamily member 11b (*TNFRSF11B*), programmed cell death 4 (*PDCD4*), diacylglycerol kinase gamma (*DGKG*), craniofacial development protein 1 (*CFDP1*), growth arrest-specific 1 (*GAS1*), paired box 6 (*PAX6*), bone marrow stromal cell antigen 2 (*BST2*), transforming growth factor beta receptor III (*TGFBR3*), vascular endothelial zinc finger 1 (*VEZF1*), etc. (see appendix).

Identification of *TNFRSF11B* Up- and Down-stream Development Cluster in Frontal Cortex of HIVE-Control Patients and HIVE by DAVID

We first datamined 4 lists of *TNFRSF11B* up- and down-stream genes from 12 frontal cortex of HIVE-control patients and 16 HIVE by GRNInfer respectively. With inputting 4 lists into DAVID, we further identified *TNFRSF11B* up- and down-stream development cluster of HIVE-control patients and HIVE. *TNFRSF11B* development cluster terms only in frontal cortex of HIVE-control patients cover apoptosis, plasma membrane and kinase activity, as shown in (Figure 1A, C). However, *TNFRSF11B* development cluster terms only in frontal cortex of HIVE contain T-cell mediated immunity, cell projection organization and cell motion, as shown in (Figure 1B, D). *TNFRSF11B* development cluster terms both in frontal cortex of HIVE-control patients and HIVE include developmental process, signal transduction, negative regulation of cell proliferation, RNA-binding, zinc-finger, cell development, positive regulation of biological process and cell differentiation, as shown in (Figure 1A, B, C, D).

In frontal cortex of HIVE-control patients, *TNFRSF11B* upstream showed little results without developmental process, as shown in (Figure 1A). In frontal cortex of HIVE, *TNFRSF11B* upstream modules mainly cover developmental process (*DGKG*, *PDCD4*, *TNFRSF11B*),

etc., as shown in (Figure 1B). In frontal cortex of HIVE-control patients, *TNFRSF11B* downstream modules mainly consist of developmental process (*BST2*, *DGKG*, *GAS1*, *PDCD4*, *TGFBR3*, *VEZF1*, *TNFRSF11B*), etc., as shown in (Figure 1C). In frontal cortex of HIVE, *TNFRSF11B* downstream modules mainly contain developmental process (*CFDP1*, *DGKG*, *BST2*, *PDCD4*, *GAS1*, *PAX6*, *TGFBR3*, *VEZF1*, *TNFRSF11B*), etc., as shown in (Figure 1D).

TNFRSF11B Up- and Down-stream Development Network Construction in Frontal Cortex of HIVE-Control Patients and HIVE


In frontal cortex of HIVE-control patients, *TNFRSF11B* upstream development network appeared no result, as shown in (Figure 2A), whereas in frontal cortex of HIVE, *TNFRSF11B* upstream development network showed that *DGKG*, *PDCD4* activate *TNFRSF11B*, as shown in (Figure 2B).

In frontal cortex of HIVE-control patients, *TNFRSF11B* downstream development network reflected that *TNFRSF11B* inhibits *BST2*, *DGKG*, *GAS1*, *PDCD4*, *TGFBR3*, *VEZF1*, as shown in (Figure 2C), whereas in frontal cortex of HIVE, *TNFRSF11B* downstream development network appeared that *TNFRSF11B* activates *CFDP1*, *DGKG*, *GAS1*, *PAX6* and inhibits *BST2*, *PDCD4*, *TGFBR3*, *VEZF1*, as shown in (Figure 2D).

Discussion

We have already done some works in this relative field about gene network construction and analysis presented in our published papers [15-19]. By integration of gene regulatory network infer (GRNInfer) and the database for annotation, visualization and integrated discovery (DAVID) we constructed significant molecule *TNFRSF11B* development network and compared *TNFRSF11B* up- and down-stream gene numbers of activation and inhibition between HIVE-control patients and HIVE (Table 1).

In *TNFRSF11B* developmental process of upstream network of frontal cortex of HIVE-control patients there was no result, whereas in that of HIVE, our integrative result reflected that *DGKG*, *PDCD4* activate *TNFRSF11B*. In *TNFRSF11B* developmental process of downstream network of HIVE-control patients, our integrative result illustrated that *TNFRSF11B* inhibits *BST2*, *DGKG*, *GAS1*, *PDCD4*, *TGFBR3*, *VEZF1*, whereas in that of HIVE, *TNFRSF11B* activates *CFDP1*, *DGKG*, *GAS1*, *PAX6* and inhibits *BST2*, *PDCD4*, *TGFBR3*, *VEZF1* (Figure 1, 2; Table 2). *PAX6* is identified by molecular function of transcription factor, homeobox transcription factor, nucleic acid binding and DNA-binding protein, and it is involved in biological process of nucleoside, nucleotide and nucleic acid metabolism,



metabolism and modification, protein biosynthesis, apoptosis, induction of apoptosis (DAVID). *PDCD4*'s relational study also can be presented in these papers [34-39]. *CFDP1* has been reported to have molecular function of mRNA splicing factor, select calcium binding proteins and KRAB box transcription factor, and to be concerned with biological process of mRNA

transcription regulation and cell motility (DAVID database). *CFDP1*'s relational study also can be presented in these papers [40-44]. We gained the positive result of *TNFRSF11B* developmental process through the net numbers of activation minus inhibition compared with HIVE-control patients and predicted possibly the increase of *TNFRSF11B* developmental process in HIVE.

Table 1 Up- and down-stream gene numbers of activation and inhibition of each module with *TNFRSF11B* gene in *TNFRSF11B* development cluster between frontal cortex of HIVE-control patients and HIVE

Term	<i>TNFRSF11B</i> upstream				<i>TNFRSF11B</i> downstream			
	con(act)	con(inh)	exp(act)	exp(inh)	con(act)	con(inh)	exp(act)	exp(inh)
Apoptosis	1	1			1	1		
Signal Transduction	2	1			4	4	4	5
Developmental Process			2	0	0	6	4	4

con represents control (HIVE-control patients), exp: experiment (HIVE), act: activation, inh: inhibition.

Table 2 Activation and inhibition gene names of *TNFRSF11B* up- and down-stream development cluster in frontal cortex of HIVE-control patients and HIVE.

Term	<i>TNFRSF11B</i> upstream			
	con(act)	con(inh)	exp(act)	exp(inh)
Developmental process			DGKG, PDCC4	
Term	<i>TNFRSF11B</i> downstream			
	con(act)	con(inh)	exp(act)	exp(inh)
Developmental process	BST2, DGKG, GAS1, PDCC4, TGFBR3, VEZF1		CFDP1, DGKG, GAS1, PAX6	BST2, PDCC4, TGFBR3, VEZF1

con represents control (HIVE-control patients), exp: experiment (HIVE), act: activation, inh: inhibition.

Importantly, we datamined that *TNFRSF11B* development cluster of HIVE is involved in T-cell mediated immunity, cell projection organization and cell motion (only in HIVE terms) without apoptosis, plasma membrane and kinase activity (only in HIVE-control patients terms), the condition is vital to inflammation, brain morphology and cognition impairment of HIVE. Our result demonstrated that common terms in both HIVE-control patients and HIVE include developmental process, signal transduction, negative regulation of cell proliferation, RNA-binding, zinc-finger, cell development, positive regulation of biological process and cell differentiation, therefore we deduced the stronger *TNFRSF11B* development network in HIVE consistent with our number computation. Some researchers indicated that tumor necrosis factor receptor studied to relate with inflammation, brain morphology and cognition [45,46]. Therefore, we predicted the stronger *TNFRSF11B* development function in HIVE. It would be necessary of the stronger *TNFRSF11B* development function to inflammation, brain morphology and cognition of HIVE.

Conclusions

In summary, we deduced the stronger *TNFRSF11B* developmental process in HIVE. It would be necessary of the stronger *TNFRSF11B* development function to inflammation, brain morphology and cognition of HIVE. *TNFRSF11B* development interaction module construction in HIVE can be a new route for studying the pathogenesis of HIVE.

Abbreviations

TNFRSF11B: tumor necrosis factor receptor superfamily member 11b; IFI44L: interferon-induced protein 44-like; ADH1B: alcohol dehydrogenase 1B (class I) beta polypeptide; RASGRP3: RAS guanyl releasing protein 3; MAPKAPK3: mitogen-activated protein kinase-activated protein kinase 3; CREB5: cAMP responsive element binding protein 5; MX1: myxovirus resistance 1; interferon-inducible protein p78; IFITM1: interferon induced transmembrane protein 1; MYBPC1: myosin binding protein C slow type; ROR1: receptor tyrosine kinase-like orphan receptor 1; IFI35: interferon-induced protein 35; LCAT: lecithin-cholesterol acyltransferase; ZC3HAV1: zinc finger CCCH-type antiviral 1; LY96: lymphocyte antigen 96; TSPAN4: tetraspanin 4; C10orf116: chromosome 10 open reading frame 116; DGKG: diacylglycerol kinase gamma; STAT1: signal transducer and activator of transcription 1; IFI27: interferon alpha-inducible protein 27; BST2: bone marrow stromal cell antigen 2; TGFBR3: transforming growth factor, beta receptor III; SLC16A4:

solute carrier family 16 member 4; FER1L3: myoferlin; ZNF652: zinc finger protein 652; HLA-B: hypothetical protein LOC441528; PDCC4: programmed cell death 4; SF1: splicing factor 1; CFHR1: complement factor H-related 1; CFB: complement factor B; LGALS3BP: lectin galactoside-binding soluble 3 binding protein; RDX: radixin; MT1G: metallothionein 1G; RBBP6: retinoblastoma binding protein 6; TENC1: tensin like C1 domain containing phosphatase; PAX6: paired box 6; NFAT5: nuclear factor of activated T-cells 5 tonicity-responsive; DGKG: diacylglycerol kinase, gamma; CFDP1: craniofacial development protein 1; VEZF1: vascular endothelial zinc finger 1; GAS1: growth arrest-specific 1; ATP6V0E1: ATPase H⁺ transporting lysosomal 9 kDa V0 subunit e1.

Acknowledgements

This work was supported by the National Natural Science Foundation in China (No.60871100) and the Teaching and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry. State Key Lab of Pattern Recognition Open Foundation, Key project of philosophical and social science of MOE (07JZD0005).

Author details

¹Biomedical Center, School of Electronics Engineering, Beijing University of Posts and Telecommunications, Beijing, 100876, China. ²Lab of Computational Linguistics, School of Humanities and Social Sciences, Tsinghua Univ., Beijing, 100084, China.

Authors' contributions

All authors participated in design and performance of the study, interpreted the result and contributed to writing the paper. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 29 March 2010 Accepted: 30 September 2010
 Published: 30 September 2010

References

- Masliah E, Roberts ES, Langford D, Everall I, Crews L, Adame A, Rockenstein E, Fox HS: **Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis.** *J Neuroimmunol* 2004, **157**:163-175.
- Chang L, Wang GJ, Volkow ND, Ernst T, Telang F, Logan J, Fowler JS: **Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse.** *Neuroimage* 2008, **42**:869-878.
- Descamps M, Hyare H, Stebbing J, Winston A: **Magnetic resonance imaging and spectroscopy of the brain in HIV disease.** *J HIV Ther* 2008, **13**:55-58.
- Georgiou MF, Gonenc A, Waldrop-Valverde D, Kuker RA, Ezuddin SH, Sfakianakis GN, Kumar M: **Analysis of the effects of injecting drug use and HIV-1 infection on 18F-FDG PET brain metabolism.** *J Nucl Med* 2008, **49**:1999-2005.
- Beyens G, Daroszewska A, de Freitas F, Franssen E, Vanhoenacker F, Verbruggen L, Zmierzak HG, Westhovens R, Van Offel J, Ralston SH, et al: **Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, *TNFRSF11B*, and Paget's disease of bone.** *J Bone Miner Res* 2007, **22**:1062-1071.

6. Chong B, Hegde M, Fawcner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tuysuz B, *et al*: Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. *J Bone Miner Res* 2003, **18**:2095-2104.
7. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawcner M, *et al*: A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. *Hum Mol Genet* 2002, **11**:2119-2127.
8. Janssens K, de Vernejoul MC, de Freitas F, Vanhoenacker F, Van Hul W: An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. *Bone* 2005, **36**:542-548.
9. Vidal C, Brincat M, Xuereb Anastasi A: TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta. *Maturitas* 2006, **53**:386-395.
10. Whyte MP, Singhellakis PN, Petersen MB, Davies M, Totty WG, Mumm S: Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. *J Bone Miner Res* 2007, **22**:938-946.
11. Storey JD: A direct approach to false discovery rates. *J Roy Stat Soc, Ser B* 2002, **64**:479-498.
12. Wang Y, Joshi T, Zhang XS, Xu D, Chen L: Inferring gene regulatory networks from multiple microarray datasets. *Bioinformatics* 2006, **22**:2413-2420.
13. Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA: The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. *Genome Biol* 2007, **8**: R183.
14. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol* 2003, **4**:P3.
15. Sun Y, Wang L, Jiang M, Huang J, Liu Z, Wolff S: Secreted Phosphoprotein 1 Upstream Invasive Network Construction and Analysis of Lung Adenocarcinoma Compared with Human Normal Adjacent Tissues by Integrative Bio-computation. *Cell Biochem Biophys* 2009, ISSN: 1085-9195 (Print) 1559-0283 (Online).
16. Sun Y, Wang L, Lui L: Integrative decomposition procedure and Kappa statistics set up ATF2 ion binding module in Malignant Pleural Mesothelioma (MPM). *Frontiers of Electrical and Electronic Engineering in China* 2008, **3**:381-387.
17. Wang L, Huang J, Jiang M, Zheng X: AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues. *Tumour Biol* .
18. Wang L, Sun Y, Jiang M, Zhang S, Wolff S: FOS proliferating network construction in early colorectal cancer (CRC) based on integrative significant function cluster and inferring analysis. *Cancer Invest* 2009, **27**:816-824.
19. Wang L, Sun Y, Jiang M, Zheng X: Integrative decomposition procedure and Kappa statistics for the distinguished single molecular network construction and analysis. *J Biomed Biotechnol* 2009, **726728**.
20. Rath MF, Bailey MJ, Kim JS, Coon SL, Klein DC, Moller M: Developmental and daily expression of the Pax4 and Pax6 homeobox genes in the rat retina: localization of Pax4 in photoreceptor cells. *J Neurochem* 2008.
21. Sjodal M, Gunhaga L: Expression patterns of Shh, Ptc2, Raldh3, Pitx2, Isl1, Lim3 and Pax6 in the developing chick hypophyseal placode and Rathke's pouch. *Gene Expr Patterns* 2008, **8**:481-485.
22. Suter DM, Tirefort D, Julien S, Krause KH: A Sox1 to Pax6 switch drives neuroectoderm to radial glia progression during differentiation of mouse embryonic stem cells. *Stem Cells* 2008.
23. Tuoc TC, Stoykova A: Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteasome system. *Genes Dev* 2008, **22**:1972-1986.
24. Villarreal CE, Villanueva-Mendoza C, Orozco L, Alcantara-Ortigoza MA, Jimenez DF, Ordaz JC, Gonzalez-del Angel A: Molecular analysis of the PAX6 gene in Mexican patients with congenital aniridia: report of four novel mutations. *Mol Vis* 2008, **14**:1650-1658.
25. Wen JH, Chen YY, Song SJ, Ding J, Gao Y, Hu QK, Feng RP, Liu YZ, Ren GC, Zhang CY, *et al*: Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3). *Diabetologia* 2008.
26. Hozumi Y, Fukaya M, Adachi N, Saito N, Otani K, Kondo H, Watanabe M, Goto K: Diacylglycerol kinase beta accumulates on the perisynaptic site of medium spiny neurons in the striatum. *Eur J Neurosci* 2008, **28**:2409-2422.
27. Hozumi Y, Watanabe M, Otani K, Goto K: Diacylglycerol kinase beta promotes dendritic outgrowth and spine maturation in developing hippocampal neurons. *BMC Neurosci* 2009, **10**:99.
28. Nakano T, Hozumi Y, Ali H, Saino-Saito S, Kamii H, Sato S, Kayama T, Watanabe M, Kondo H, Goto K: Diacylglycerol kinase zeta is involved in the process of cerebral infarction. *Eur J Neurosci* 2006, **23**:1427-1435.
29. Nakano T, Iseki K, Hozumi Y, Kawamae K, Wakabayashi I, Goto K: Brain trauma induces expression of diacylglycerol kinase zeta in microglia. *Neurosci Lett* 2009, **461**:110-115.
30. Gobeil S, Zhu X, Doillon CJ, Green MR: A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. *Genes Dev* 2008, **22**:2932-2940.
31. Hirayama H, Fujita M, Yoko-o T, Jigami Y: O-mannosylation is required for degradation of the endoplasmic reticulum-associated degradation substrate Gas1*p via the ubiquitin/proteasome pathway in *Saccharomyces cerevisiae*. *J Biochem* 2008, **143**:555-567.
32. Lopez-Ramirez MA, Dominguez-Monzon G, Vergara P, Segovia J: Gas1 reduces Ret tyrosine 1062 phosphorylation and alters GDNF-mediated intracellular signaling. *Int J Dev Neurosci* 2008, **26**:497-503.
33. Seppala M, Depew MJ, Martinelli DC, Fan CM, Sharpe PT, Cobourne MT: Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog. *J Clin Invest* 2007, **117**:1575-1584.
34. Lankat-Buttgereit B, Muller S, Schmidt H, Parhofer KG, Gress TM, Goke R: Knockdown of Pdc4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. *Biol Cell* 2008, **100**:703-715.
35. Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, Colburn NH: Translation inhibitor Pdc4 is targeted for degradation during tumor promotion. *Cancer Res* 2008, **68**:1254-1260.
36. Suzuki C, Garces RG, Edmonds KA, Hiller S, Hyberts SG, Marintchev A, Wagner G: PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. *Proc Natl Acad Sci USA* 2008, **105**:3274-3279.
37. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R, Verde P: An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. *Oncogene* 2008.
38. Wang Q, Sun Z, Yang HS: Downregulation of tumor suppressor Pdc4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. *Oncogene* 2008, **27**:1527-1535.
39. Wang X, Wei Z, Gao F, Zhang X, Zhou C, Zhu F, Wang Q, Gao Q, Ma C, Sun W, *et al*: Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. *Anticancer Res* 2008, **28**:2991-2996.
40. Diekwisch TG, Luan X: CP27 function is necessary for cell survival and differentiation during tooth morphogenesis in organ culture. *Gene* 2002, **287**:141-147.
41. Diekwisch TG, Luan X, McIntosh JE: CP27 localization in the dental lamina basement membrane and in the stellate reticulum of developing teeth. *J Histochem Cytochem* 2002, **50**:583-586.
42. Iwashita S, Itoh T, Takeda H, Sugimoto Y, Takahashi I, Nobukuni T, Sezaki M, Masui T, Hashimoto K: Gene organization of bovine BCNT that contains a portion corresponding to an endonuclease domain derived from an RTE-1 (Bov-B LINE), non-LTR retrotransposable element: duplication of an intramolecular repeat unit downstream of the truncated RTE-1. *Gene* 2001, **268**:59-66.
43. Iwashita S, Osada N, Itoh T, Sezaki M, Oshima K, Hashimoto E, Kitagawa-Arita Y, Takahashi I, Masui T, Hashimoto K, Makalowski W: A transposable element-mediated gene divergence that directly produces a novel type bovine Bcnt protein including the endonuclease domain of RTE-1. *Mol Biol Evol* 2003, **20**:1556-1563.
44. Luan X, Diekwisch TG: CP27 affects viability, proliferation, attachment and gene expression in embryonic fibroblasts. *Cell Prolif* 2002, **35**:207-219.
45. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD: Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. *Alzheimer Dis Assoc Disord* 1998, **12**:215-227.

46. Wassink TH, Crowe RR, Andreasen NC: **Tumor necrosis factor receptor-II: heritability and effect on brain morphology in schizophrenia.** *Mol Psychiatry* 2000, **5**:678-682.

doi:10.1186/1476-9255-7-50

Cite this article as: Huang *et al.*: *TNFRSF11B* computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients. *Journal of Inflammation* 2010 **7**:50.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

